Skip to main content
Premium Trial:

Request an Annual Quote

Med BioGene Reports No Revenues in Q1; Loss Narrows

NEW YORK (GenomeWeb News) – Med BioGene today reported no revenues for the first quarter, the same as in the first quarter of 2012.

For the three months ended March 31, the Vancouver, British Columbia-based molecular diagnostics firm said the comprehensive loss totaled $74,133, or breakeven, compared to a loss of $120,701, or breakeven, a year ago, according to a document filed with Canadian regulators.

SG&A costs were lowered 35 percent to $78,414 from $121,296.

Med BioGene reported $291,717 in cash and cash equivalents at the end of the quarter.

During the quarter, Precision Therapeutics completed its clinical studies validating the use of its GeneFx diagnostic test for identifying patients with early stage, non-small-cell lung cancer who, following surgical removal of their tumor, are at higher or lower risks of mortality. The test was previously called LungExpress Dx.

Med BioGene previously said it anticipates making the test commercially available mid-year.

In 2011, Signal Genetics and Respira Health sued Med BioGene alleging a breach of agreement, violation of a confidentiality agreement, and misuse of proprietary information, among other charges. In February, Med BioGene said that the Supreme Court of the State of New York granted its motion to dismiss claims by the plaintiffs for lost-profit damages arising from alleged breaches of contract, as well as a cause of action for negligent misrepresentation and a cause of action for unfair competition.

Erinn Broshko, executive chairman of the company, said today in a statement that the company is "confident that we will be successful in having the remaining claims and causes of action dismissed."

This month, 2.3 million warrants and agents' warrants to purchase an equal number of common shares at $0.10 per share were exercised, providing Med BioGene gross proceeds of $231,800. As a result, it had $470,000 in cash and cash equivalents as of May 28, it said.

The Scan

Drug Response Variants May Be Distinct in Somatic, Germline Samples

Based on variants from across 21 drug response genes, researchers in The Pharmacogenomics Journal suspect that tumor-only DNA sequences may miss drug response clues found in the germline.

Breast Cancer Risk Gene Candidates Found by Multi-Ancestry Low-Frequency Variant Analysis

Researchers narrowed in on new and known risk gene candidates with variant profiles for almost 83,500 individuals with breast cancer and 59,199 unaffected controls in Genome Medicine.

Health-Related Quality of Life Gets Boost After Microbiome-Based Treatment for Recurrent C. Diff

A secondary analysis of Phase 3 clinical trial data in JAMA Network Open suggests an investigational oral microbiome-based drug may lead to enhanced quality of life measures.

Study Follows Consequences of Early Confirmatory Trials for Accelerated Approval Indications

Time to traditional approval or withdrawal was shorter when confirmatory trials started prior to accelerated approval, though overall regulatory outcomes remained similar, a JAMA study finds.